Drugs / INBRX-105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03809624 | Jan 2019 → Oct 2024 | esophageal adenocarcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, melanoma +5 | Inhibrx Biosciences, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-06-30 | Inhibrx Biosciences, Inc | Results Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance investorroom.com ↗ |
| 2021-03-12 | Inhibrx Biosciences, Inc | Results Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist investorroom.com ↗
We observed dose-limiting toxicities, which were consistent with immune related adverse events (for example, hepatitis, arthritis and myalgia/hyperthyroidism) at several dose levels and determined the 1 mg/kg dose level as the MTD of INBRX-105. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INBRX-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03809624 ↗ |
| Action | Activate | “INBRX-105 provides localized conditional T-cell co-stimulation through 4-1BB agonism.” NCT03809624 ↗ |